ProShares UltraShort NASDAQ Biotechnology
13 hedge funds and large institutions have $19.9M invested in ProShares UltraShort NASDAQ Biotechnology in 2015 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Holders
13
Holding in Top 10
1
Calls
$1.76M
Puts
$704K
Top Buyers
| 1 | +$3.45M | |
| 2 | +$966K | |
| 3 | +$874K | |
| 4 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$863K |
| 5 |
Goldman Sachs
New York
|
+$214K |
Top Sellers
| 1 | -$1.36M | |
| 2 | -$225K | |
| 3 | -$215K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$195K |
| 5 |
Morgan Stanley
New York
|
-$19.5K |